We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The healthcare space has been less intriguing than other areas of the economy with notable stocks like Bristol Myers (BMY - Free Report) ), Gilead Sciences (GILD - Free Report) ), and Pfizer (PFE - Free Report) ) all down sharply this year.
Still, there is no question as to the importance healthcare has to society and a few Zacks Medical sector stocks are starting to stand out at the moment.
Here are two top-rated Medical stocks that investors may want to consider buying right now.
Sporting a Zacks Rank #1 (Strong Buy) HealthEquity’s stock is very attractive at the moment with the company’s outlook starting to brighten.
HealthEquity is a provider of integrated solutions for healthcare account management, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States.
Image Source: Zacks Investment Research
Standing out among the Zacks Medical Services Industry, HealthEquity’s sales are forecasted be rise 13% in its current fiscal 2024 and jump another 13% in FY25 to $1.1 billion.
Even better, while HealthEquity’s stock has been virtually flat this year there could be more upside ahead as earnings estimate revisions have trended higher over the last quarter.
HealthEquity’s earnings are now expected to climb 35% in FY24 at $1.84 per share compared to EPS of $1.36 in FY23. More impressive, FY25 earnings are projected to soar another 29% at $2.38 per share.
Among the Zacks Medical-Instruments Industry, iRadimed’s stock looks attractive with a Zacks Rank #2 (Buy).
iRadimed provides a broad range of magnetic resonance imaging (MRI) compatible products with earnings estimates remaining higher and supportive of this year’s rally in shares of IRMD.
Notably, iRadimed stock has soared +69% YTD to largely outperform the broader indexes and obliterate the Zacks Medical-Instrument Markets’+6%.
This has also crushed the lackluster stock performances of healthcare giants Bristol Myers, Gilead Sciences, and Pfizer.
Image Source: Zacks Investment Research
iRadimed’s earnings are now anticipated to jump 19% this year at $1.31 per share compared to EPS of $1.10 in 2022. Plus, fiscal 2024 earnings are forecasted to rise another 14% at $1.50 per share.
Solid top-line growth is also expected, with sales projected to climb 19% in FY23 and rise another 11% in FY24 to $70.30 million.
Image Source: Zacks Investment Research
Bottom Line
The outlook for these top-rated Zacks Medical sector stocks is very intriguing making them worthy of investors’ consideration. With solid top and bottom-line growth on the horizon for HealthEquity and iRadimed, they are starting to look like viable investments for 2023 and beyond.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
2 Medical Stocks to Consider Buying in June
The healthcare space has been less intriguing than other areas of the economy with notable stocks like Bristol Myers (BMY - Free Report) ), Gilead Sciences (GILD - Free Report) ), and Pfizer (PFE - Free Report) ) all down sharply this year.
Still, there is no question as to the importance healthcare has to society and a few Zacks Medical sector stocks are starting to stand out at the moment.
Here are two top-rated Medical stocks that investors may want to consider buying right now.
HealthEquity (HQY - Free Report) )
Sporting a Zacks Rank #1 (Strong Buy) HealthEquity’s stock is very attractive at the moment with the company’s outlook starting to brighten.
HealthEquity is a provider of integrated solutions for healthcare account management, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States.
Image Source: Zacks Investment Research
Standing out among the Zacks Medical Services Industry, HealthEquity’s sales are forecasted be rise 13% in its current fiscal 2024 and jump another 13% in FY25 to $1.1 billion.
Even better, while HealthEquity’s stock has been virtually flat this year there could be more upside ahead as earnings estimate revisions have trended higher over the last quarter.
HealthEquity’s earnings are now expected to climb 35% in FY24 at $1.84 per share compared to EPS of $1.36 in FY23. More impressive, FY25 earnings are projected to soar another 29% at $2.38 per share.
Image Source: Zacks Investment Research
iRadimed (IRMD - Free Report) )
Among the Zacks Medical-Instruments Industry, iRadimed’s stock looks attractive with a Zacks Rank #2 (Buy).
iRadimed provides a broad range of magnetic resonance imaging (MRI) compatible products with earnings estimates remaining higher and supportive of this year’s rally in shares of IRMD.
Notably, iRadimed stock has soared +69% YTD to largely outperform the broader indexes and obliterate the Zacks Medical-Instrument Markets’+6%.
This has also crushed the lackluster stock performances of healthcare giants Bristol Myers, Gilead Sciences, and Pfizer.
Image Source: Zacks Investment Research
iRadimed’s earnings are now anticipated to jump 19% this year at $1.31 per share compared to EPS of $1.10 in 2022. Plus, fiscal 2024 earnings are forecasted to rise another 14% at $1.50 per share.
Solid top-line growth is also expected, with sales projected to climb 19% in FY23 and rise another 11% in FY24 to $70.30 million.
Image Source: Zacks Investment Research
Bottom Line
The outlook for these top-rated Zacks Medical sector stocks is very intriguing making them worthy of investors’ consideration. With solid top and bottom-line growth on the horizon for HealthEquity and iRadimed, they are starting to look like viable investments for 2023 and beyond.